Details for New Drug Application (NDA): 209817

✉ Email this page to a colleague

NDA 209817 describes NUZYRA, which is a drug marketed by Paratek Pharms and is included in two NDAs. It is available from one supplier. There are eight patents protecting this drug. Additional details are available on the NUZYRA profile page.

The generic ingredient in NUZYRA is omadacycline tosylate. One supplier is listed for this compound. Additional details are available on the omadacycline tosylate profile page.

Summary for 209817

Tradename:	NUZYRA
Applicant:	Paratek Pharms
Ingredient:	omadacycline tosylate
Patents:	5

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 209817

Generic Entry Date for 209817^: ⤷ Get Started Free* Constraining patent/regulatory exclusivity: GENERATING ANTIBIOTIC INCENTIVES NOW Dosage: POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 209817

Suppliers and Packaging for NDA: 209817

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817	NDA	Paratek Pharmaceuticals, Inc.	71715-001	71715-001-02	10 VIAL, GLASS in 1 CARTON (71715-001-02) / 10 mL in 1 VIAL, GLASS (71715-001-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;INTRAVENOUS			Strength	EQ 100MG BASE/VIAL
Approval Date:	Oct 2, 2018	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	Oct 2, 2028
Regulatory Exclusivity Use:	GENERATING ANTIBIOTIC INCENTIVES NOW
Regulatory Exclusivity Expiration:	Oct 2, 2023
Regulatory Exclusivity Use:	NEW CHEMICAL ENTITY
Patent:	10,124,014	Patent Expiration:	Mar 5, 2029	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION

Expired US Patents for NDA 209817

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Paratek Pharms	NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817-001	Oct 2, 2018	7,326,696	⤷ Get Started Free
Paratek Pharms	NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817-001	Oct 2, 2018	7,553,828	⤷ Get Started Free
Paratek Pharms	NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817-001	Oct 2, 2018	9,365,500	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.